283 related articles for article (PubMed ID: 34802772)
41. Acceptability of Naloxone Co-Prescription Among Primary Care Providers Treating Patients on Long-Term Opioid Therapy for Pain.
Behar E; Rowe C; Santos GM; Coffa D; Turner C; Santos NC; Coffin PO
J Gen Intern Med; 2017 Mar; 32(3):291-295. PubMed ID: 27815762
[TBL] [Abstract][Full Text] [Related]
42. Barriers to primary care physicians prescribing buprenorphine.
Hutchinson E; Catlin M; Andrilla CH; Baldwin LM; Rosenblatt RA
Ann Fam Med; 2014; 12(2):128-33. PubMed ID: 24615308
[TBL] [Abstract][Full Text] [Related]
43. Interrupted Time Series of User-centered Clinical Decision Support Implementation for Emergency Department-initiated Buprenorphine for Opioid Use Disorder.
Holland WC; Nath B; Li F; Maciejewski K; Paek H; Dziura J; Rajeevan H; Lu CC; Katsovich L; D'Onofrio G; Melnick ER
Acad Emerg Med; 2020 Aug; 27(8):753-763. PubMed ID: 32352206
[TBL] [Abstract][Full Text] [Related]
44. Take -home naloxone rescue kits following heroin overdose in the emergency department to prevent opioid overdose related repeat emergency department visits, hospitalization and death- a pilot study.
Papp J; Vallabhaneni M; Morales A; Schrock JW
BMC Health Serv Res; 2019 Dec; 19(1):957. PubMed ID: 31829228
[TBL] [Abstract][Full Text] [Related]
45. An opioid overdose curriculum for medical residents: Impact on naloxone prescribing, knowledge, and attitudes.
Taylor JL; Rapoport AB; Rowley CF; Mukamal KJ; Stead W
Subst Abus; 2018; 39(3):371-376. PubMed ID: 29432074
[TBL] [Abstract][Full Text] [Related]
46. Rate of patients at elevated risk of opioid overdose visiting the emergency department.
Pedigo JR; Seifert CF
Am J Emerg Med; 2018 Dec; 36(12):2161-2165. PubMed ID: 29602664
[TBL] [Abstract][Full Text] [Related]
47. A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions.
Pourmand A; Beisenova K; Shukur N; Tebo C; Mortimer N; Mazer-Amirshahi M
Am J Emerg Med; 2021 Oct; 48():316-322. PubMed ID: 34274576
[TBL] [Abstract][Full Text] [Related]
48. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
[TBL] [Abstract][Full Text] [Related]
49. Patterns of buprenorphine/naloxone prescribing: an analysis of claims data from Massachusetts.
Paulsen R; Modestino AS; Hasan MM; Noor-E-Alam M; Young LD; Young GJ
Am J Drug Alcohol Abuse; 2020; 46(2):216-223. PubMed ID: 31825718
[No Abstract] [Full Text] [Related]
50. Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties.
Cerdá M; Hamilton AD; Hyder A; Rutherford C; Bobashev G; Epstein JM; Hatna E; Krawczyk N; El-Bassel N; Feaster DJ; Keyes KM
Epidemiology; 2024 May; 35(3):418-429. PubMed ID: 38372618
[TBL] [Abstract][Full Text] [Related]
51. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States.
Smart R; Pardo B; Davis CS
Addiction; 2021 Jan; 116(1):6-17. PubMed ID: 32533570
[TBL] [Abstract][Full Text] [Related]
52. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use.
Kaur AD; McQueen A; Jan S
J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120
[TBL] [Abstract][Full Text] [Related]
53. Results From the POINT Pragmatic Randomized Trial: An Emergency Department-Based Peer Support Specialist Intervention to Increase Opioid Use Disorder Treatment Linkage and Reduce Recurrent Overdose.
Watson DP; Tillson M; Taylor L; Xu H; Ouyang F; Beaudoin FL; O'Donnell D; McGuire AB
Subst Use Addctn J; 2024 Jul; 45(3):378-389. PubMed ID: 38258819
[TBL] [Abstract][Full Text] [Related]
54. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.
Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
Curr Med Res Opin; 2014 Aug; 30(8):1579-87. PubMed ID: 24689806
[TBL] [Abstract][Full Text] [Related]
55. Implementation and maintenance of an emergency department naloxone distribution and peer recovery specialist program.
Jacka BP; Ziobrowski HN; Lawrence A; Baird J; Wentz AE; Marshall BDL; Wightman RS; Mello MJ; Beaudoin FL; Samuels EA
Acad Emerg Med; 2022 Mar; 29(3):294-307. PubMed ID: 34738277
[TBL] [Abstract][Full Text] [Related]
56. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
57. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.
Coffin PO; Behar E; Rowe C; Santos GM; Coffa D; Bald M; Vittinghoff E
Ann Intern Med; 2016 Aug; 165(4):245-52. PubMed ID: 27366987
[TBL] [Abstract][Full Text] [Related]
58. Analysis of rising cases of adolescent opioid use presentations to the emergency department and their management.
Sidlak A; Dibble B; Dhaliwal M; Bottone P; Marino R; Henry L; Howell J
Drug Alcohol Depend; 2024 May; 258():111136. PubMed ID: 38518662
[TBL] [Abstract][Full Text] [Related]
59. Continuation of outpatient buprenorphine therapy after dispensing Buprenorphine-Naloxone from the emergency department.
Krenz JR; Hayes BD; Wakeman SE; Martin A; Raja AS; White BA; Koehl JL
Clin Toxicol (Phila); 2022 Apr; 60(4):429-432. PubMed ID: 34409916
[TBL] [Abstract][Full Text] [Related]
60. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
Currie JM; Schnell MK; Schwandt H; Zhang J
JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
